The Rural Health Clinic COVID-19 Therapeutics (RHCTH) Program provides access to oral antiviral medications (therapeutics) to eligible CMS-certified Rural Health Clinics (RHCs) by:
- Supplementing state/jurisdictional allocations of antiviral medications to increase the availability of COVID-19 therapeutics in rural communities.
- Supplementing state/jurisdictional allocations of antiviral medications to ensure those disproportionately affected by COVID-19 have equitable access to FDA-authorized or approved COVID-19 therapeutics.
HRSA began incremental RHCTH Program enrollment in June 2022 for RHCs already enrolled in the Health Partner Order Portal (HPOP) through participation in the RHC COVID-19 Testing Supply (RHCCTS) Program and/or RHC COVID-19 Vaccine Distribution (RHCVD) Program and with existing legal allowance to prescribe and dispense at point-of-care or with pharmacy capacity.
As of July 2022, additional RHCs may enroll in the RHCTH Program regardless of current HPOP enrollment or participation in other RHC COVID-19 programs.
- CMS-certified RHCs and organizations that own and operate CMS-certified RHCs.
- All RHCs must have active CMS Certification Numbers (CCNs).
- Verify your RHC provider type eligibility and obtain your RHC CCN on the CMS Quality, Certification and Oversight Reports (QCOR) website;
- Once your RHC CCN is confirmed, email RHCtreatment@hrsa.gov for additional enrollment instructions.
HRSA will enroll RHCs in the Therapeutics Program as they meet eligibility requirements. You will receive an email confirmation once enrolled.
- HRSA funded the National Association of Rural Health Clinics (NARHC) to provide technical assistance to RHCs participating in the COVID-19 Therapeutics Program.
- For more details on the RHCTH Program and additional enrollment resources visit NARHC HRSA Rural Health Clinic COVID-19 Therapeutics Program FAQs or email email@example.com
For questions about the RHC COVID-19 Therapeutics Program, email RHCTreatment@hrsa.gov.